Shares of Moderna (MRNA), one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, were up nearly 10% in early trading after the first death from the bird flu was reported in the U.S., Barron’s reports. As of Monday, there had been 66 confirmed human cases of H5N1 bird flu in the U.S. since 2024 and 67 since 2022, according to Centers for Disease Control and Prevention data. Pfizer (PFE) and GSK (GSK), in partnership with CureVac (CVAC) are also developing bird flu mRNA vaccines. Pfizer gained nearly 2%, while GSK was up 1%, and CureVac was up 3%.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRNA:
- Early notable gainers among liquid option names on January 7th
- SPY ETF News, 1/7/2025
- VOO ETF News, 1/6/2025
- Early notable gainers among liquid option names on December 31st
- SPY ETF Update, 12/31/2024
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
